Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab in RIC for High Risk B-NHL Allo-HSCT
NCT01613300Phase 2Completed
- Sponsor
- GELTAMO
- Start
- Apr 2012
- Primary completion
- Jun 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ofatumumab in B-cell non-Hodgkin lymphoma, sponsored by GELTAMO. Started Apr 2012; status: completed.
02
Drugs
ofatumumab
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT01613300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01613300.